Since we found that IRGM negatively regulates RIPK2‐dependent pro‐inflammatory responses, we hypothesized that therapeutic inhibition of RIPK2 could reduce gut inflammation associated with Irgm1 depletion in shigellosis‐ and DSS‐induced colitis models. The gene discussed is RIPK2; the disease is inflammation.